James Edgemond, the Chief Financial Officer of United Therapeutics, has executed a sale of company stock valued at $5.7 million. This transaction reflects Edgemond's decision to divest a portion of his holdings in the biopharmaceutical firm. The sale is part of his financial management strategy, although specific details regarding the timing and purpose of the sale have not been disclosed.
Related Articles
Don't miss out on breaking stories and in-depth articles.